Merck didn't pay the high price for a new class of antibiotic. Brilacidin is a new class. While I agree it hurt not to move forward with it, I understand why the company had to change gears while dealing with the fallout from multiple distorted hit pieces in 2015.
Fortunately, for us shareholders, we are very close to getting the Brilacidin OM results and I'll be surprised if they aren't in line with the excellent interim results. ;)
In Reply to 'baytdr'
Merck paid $8.4 Billion for Cubist's Dapto and a pipeline of unapproved antibiotics. I remain disappointed and flummoxed that Leo didn't/couldn't find a partner for B-Absssi. I firmly believe this single disappointment, more than any other issue depresses the SP to this day and will until a credible partner is signed to a material deal which I assume will be B-OM this Q. I anticipate that a B-OM partnership will increase interest in the entire B franchise, including Absssi.
Market Data 
Markets 
AI
